A modular and controllable T cell therapy platform for acute myeloid leukemia

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Targeted T cell therapy shows efficacy when tumor antigens are uniformly expressed and off-tumor toxicity is manageable.
• Acute myeloid leukemia (AML) is T cell-sensitive, but current T cell therapies have failed due to lack of selective, uniformly expressed targets and risk of myeloid toxicity.

Purpose of the Study:

• To develop a modular and controllable MHC-unrestricted adoptive T cell therapy platform specifically for AML.
• To overcome the limitations of existing T cell therapies in AML treatment.

Main Methods:

• Development of a platform combining synthetic agonistic receptor (SAR)-transduced T cells with AML-targeting tandem single chain variable fragment (scFv) constructs.
• Utilizing construct exchange for SAR T cell redirection based on the short half-life and controllability of antibody fragments.

Main Results:

• Selective killing of CD33+ and CD123+ AML cell lines and patient-derived AML blasts was achieved.
• Durable responses and persistence of SAR-transduced T cells were observed in AML xenograft models.

Conclusions:

• The developed modular and controllable T cell therapy platform demonstrates potential for selective AML targeting.
• These findings support further translation of this novel platform for effective AML treatment.